3 research outputs found
Investigation of Immune Biomarkers Using Subcutaneous Model of M. tuberculosis Infection in BALB/c Mice: A Preliminary Report
Evaluation and screening of vaccines against tuberculosis
depends on development of proper cost effective disease
models along with identification of different immune markers
that can be used as surrogate endpoints of protection in preclinical
and clinical studies. The objective of the present
study was therefore evaluation of subcutaneous model of
M.tuberculosis infection along with investigation of different
immune biomarkers of tuberculosis infection in BALB/c
mice. Groups of mice were infected subcutaneously with two
different doses : high (2×106
CFU) and low doses (2×102
CFU) of M.tuberculosis and immune markers including humoral
and cellular markers were evaluated 30 days post
M.tuberculosis infections. Based on results, we found that
high dose of subcutaneous infection produced chronic disease
with significant (p<0.001) production of immune markers
of infection like IFNγ, heat shock antigens (65, 71) and
antibody titres against panel of M.tuberculosis antigens
(ESAT-6, CFP-10, Ag85B, 45kDa, GroES, Hsp-16) all of
which correlated with high bacterial burden in lungs and
spleen. To conclude high dose of subcutaneous infection produces
chronic TB infection in mice and can be used as convenient
alternative to aerosol models in resource limited
settings. Moreover assessment of immune markers namely
mycobacterial antigens and antibodies can provide us valuable
insights on modulation of immune response post
infection. However further investigations along with optimization
of study protocols are needed to justify the outcome
of present study and establish such markers as surrogate
endpoints of vaccine protection in preclinical and clinical
studies in futur
Effect of repeat dose of BCG vaccination on humoral response in mice model
7-10BCG is the only vaccine presently available against
tuberculosis but it is estimated to prevent only 5% of the all potentially
vaccine-preventable deaths due to Tuberculosis. Keeping these in view the
present study has been undertaken to evaluate the efficacy of BCG and the
effect of repeat dose of BCG on antimycobacterial humoral response in mouse
model. To improve BCG immunogenicity, specific anti-mycobacterial immune
responses (anti-BCG titre and total IgG level) were evaluated in mouse model
using boost immunization protocols with the BCG vaccine. Mice
induced with a repeat dose of BCG showed an increased anti mycobacterial
humoral response, which gradually declined few weeks after single dose of BCG
administration. The results suggest improved efficacy of BCG vaccine by giving
repeat dose of BCG that can enhance the level of immunoprotection against
tuberculosis as opposed to a single BCG dose